About Zenlabs
Zenlabs is a publicly listed company based in Chandigarh (India) founded in 2008. Pharmaceutical drugs for multiple therapeutic areas are manufactured by Zenlabs. The company has 16 employees. Its chief executive, as recorded, is Sanjeev Kumar. Its Indian entity Zenlabs Ethica Limited reported revenue of ₹47.10 Cr. Zenlabs offers products and services including Analgesics and Anti-Inflammatory Drugs and Nutraceuticals. Its focus areas include Traditional Pharmaceuticals, Traditional Nutraceuticals, Diversified and Herbal.
Company details
Zenlabs was established in 2008 in Chandigarh, India, within the pharmaceutical sector. Focus is placed on the production of drugs targeting various therapeutic areas. Operations are conducted from the companys base in India, serving needs in healthcare through manufacturing processes. Leadership is provided by Managing Director and CEO Sanjeev Kumar, with regulatory details including DIN 01154896 and PAN ACSPK6038N noted for compliance. The domain zenlabsethica.com supports online presence.
- Headquarters Chandigarh, India
- Employees 16
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website zenlabsethica.com
- Social X Facebook Instagram YouTube
- Legal Name Zenlabs Ethica Ltd
- Market Cap₹17.15 Cr
ZENLABS · BSE
- Share Price₹26.95
+2.32% today
- Revenue₹46.92 Cr
FY 2025-26 · -8.8% YoY
- EBITDA−₹0.29 Cr
Margin -0.6%
- Net Profit₹0.03 Cr
FY 2025-26 · -88.9% YoY
- ROE0.2%
ROCE 4.7%
- Debt / Equity1.25
Interest cover -68.6x
- Employee Count16
Associated legal entities of Zenlabs
Zenlabs operates through Zenlabs Ethica Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Zenlabs Ethica Limited Listed CIN L74900CH1993PLC033112 | Active | 20 Jul 1993 | Chandigarh, Chandigarh | ₹47.1 Cr | 16 | 7 | View details |
Products & Services of Zenlabs
Zenlabs offers a comprehensive portfolio of products and services, including Analgesics and Anti-Inflammatory Drugs and Nutraceuticals.
These drugs are manufactured for the treatment of pain and inflammation.
Nutraceuticals are provided to support nutritional needs and overall health.
Apps and channels of Zenlabs
its YouTube channel ZENOVIT has 79 subscribers and 17 videos.
Videos from Zenlabs
The most watched videos on Zenlabs's YouTube channel, ZENOVIT (79 subscribers). Click a video to play it here.
More on ZENOVIT.
Board of directors of Zenlabs Ethica Limited (Zenlabs)
Zenlabs Ethica Limited is the primary company behind Zenlabs. The board of Zenlabs Ethica Limited currently have 5 directors; the longest-serving is Sanjeev Singal, appointed in 2008. 23 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sanjeev Singal DIN 01154896 | Managing Director | 27 Aug 2008 | 18 yrs 1 mo | Zenlabs Ethica Limited |
| Himjyoti DIN 02398927 | Director | 25 Mar 2015 | 11 yrs 6 mo | Zenlabs Ethica Limited |
| Anurag Malhotra DIN 07552713 | Director | 11 Aug 2016 | 10 yrs 2 mo | Zenlabs Ethica Limited |
| Sanjay Dhir DIN 02452461 | Whole-time director | 11 Aug 2016 | 10 yrs 2 mo | Zenlabs Ethica Limited |
| Kuldeep Singh DIN 08454422 | Director | 10 Jun 2019 | 7 yrs 4 mo | Zenlabs Ethica Limited |
People of Zenlabs
1 people are tracked at Zenlabs (1 in leadership); the tracked headcount is 16.
| Name | Role | Group |
|---|---|---|
| Managing Director & CEO | Leadership |
Complete people profiles for Zenlabs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Zenlabs
Zenlabs is a publicly listed company on the BSE with ticker symbol ZENLABS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 May 1995
- Listed onBSE: 530697
- Listed entityZenlabs Ethica Ltd
- Exchange sectorHealth technology
- ISININE546F01013
- Share price₹26.29 (-1.57% on the day) · 2026-10-13
- Volume (last session)1,203
Financials of Zenlabs
Exchange-reported figures of Zenlabs Ethica Limited, the listed company behind Zenlabs (BSE: ZENLABS).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 46.92 | 51.42 | 58.56 | 66.89 | 69.09 | 56.64 | 59.95 |
| Revenue growth | -8.8% | -12.2% | -12.5% | -3.2% | +22.0% | -5.5% | - |
| EBITDA | (0.29) | 2.57 | 2.40 | 2.34 | 2.41 | 1.73 | (0.70) |
| EBITDA margin | -0.6% | +5.0% | +4.1% | +3.5% | +3.5% | +3.1% | -1.2% |
| Profit before tax | (1.81) | 0.43 | 0.58 | 0.69 | 1.24 | 0.85 | (1.17) |
| Net profit | 0.03 | 0.27 | 0.42 | 0.92 | 0.80 | 0.77 | (0.74) |
| Net profit margin | +0.1% | +0.5% | +0.7% | +1.4% | +1.2% | +1.4% | -1.2% |
| EPS (₹) | (2.97) | 0.41 | 0.65 | 0.75 | 1.20 | 1.18 | (1.13) |
| Balance sheet | |||||||
| Total assets | 20.58 | 24.63 | 26.50 | 16.86 | 14.51 | 11.45 | 8.51 |
| Net worth | 8.51 | 10.43 | 10.12 | 9.70 | 9.33 | 8.56 | 7.41 |
| Total debt | 10.98 | 12.71 | 14.86 | 5.85 | 3.90 | 2.60 | 0.73 |
| Cash & bank | 2.91 | 1.80 | 0.93 | 1.64 | 1.51 | 1.70 | 2.09 |
| Net working capital | 18.47 | 21.37 | 21.80 | 10.87 | 10.03 | 6.74 | 6.34 |
| Cash flow | |||||||
| Cash from operations | 4.06 | 3.83 | (9.06) | 1.52 | (0.38) | (8.41) | 0.45 |
| Cash from investing | 0.00 | 0.14 | 0.11 | (1.47) | 0.00 | 0.15 | 0.01 |
| Cash from financing | (2.95) | (3.08) | 8.24 | 0.06 | 0.31 | (0.52) | (0.03) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.18 | 10.58 | 12.43 | 12.43 | 11.48 | 12.99 | 12.72 | 13.35 |
| Revenue growth (YoY) | +23.5% | -18.6% | -2.3% | -6.9% | -7.1% | - | - | - |
| Other income | 0.00 | 0.12 | 0.00 | 0.06 | 0.00 | 0.04 | 0.00 | 0.00 |
| Total expenses | 14.47 | 10.30 | 13.99 | 11.99 | 10.93 | 12.33 | 12.04 | 12.73 |
| EBITDA | (0.29) | 0.28 | (1.56) | 0.44 | 0.55 | 0.66 | 0.68 | 0.62 |
| EBITDA margin | -2.0% | +2.6% | -12.6% | +3.5% | +4.8% | +5.1% | +5.3% | +4.6% |
| Depreciation | 0.11 | 0.14 | 0.23 | 0.24 | 0.29 | 0.31 | 0.32 | 0.31 |
| Interest | 0.16 | 0.18 | 0.23 | 0.19 | 0.21 | 0.23 | 0.24 | 0.23 |
| Profit before tax | (0.56) | 0.08 | (2.02) | 0.07 | 0.05 | 0.16 | 0.12 | 0.08 |
| Tax | 0.02 | 0.08 | 0.00 | 0.04 | 0.01 | 0.07 | 0.04 | 0.02 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.18 | 10.58 | 12.43 | 12.43 | 11.48 | 12.99 | 12.72 | 13.35 |
| Revenue growth (YoY) | +23.5% | -18.6% | -2.3% | -6.9% | -7.1% | - | - | - |
| Other income | 0.00 | 0.12 | 0.00 | 0.06 | 0.00 | 0.04 | 0.00 | 0.00 |
| Total expenses | 14.47 | 10.30 | 13.99 | 11.99 | 10.93 | 12.33 | 12.04 | 12.73 |
| EBITDA | (0.29) | 0.28 | (1.56) | 0.44 | 0.55 | 0.66 | 0.68 | 0.62 |
| EBITDA margin | -2.0% | +2.6% | -12.6% | +3.5% | +4.8% | +5.1% | +5.3% | +4.6% |
| Depreciation | 0.11 | 0.14 | 0.23 | 0.24 | 0.29 | 0.31 | 0.32 | 0.31 |
| Interest | 0.16 | 0.18 | 0.23 | 0.19 | 0.21 | 0.23 | 0.24 | 0.23 |
| Profit before tax | (0.56) | 0.08 | (2.02) | 0.07 | 0.05 | 0.16 | 0.12 | 0.08 |
| Tax | 0.02 | 0.08 | 0.00 | 0.04 | 0.01 | 0.07 | 0.04 | 0.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 46.92 | 51.42 | 58.56 | 66.89 | 69.09 | 56.64 | 59.95 |
| Revenue growth | -8.8% | -12.2% | -12.5% | -3.2% | +22.0% | -5.5% | - |
| Other income | 0.18 | 0.05 | 0.30 | 0.13 | 0.09 | 0.12 | 0.05 |
| Total expenses | 47.21 | 48.85 | 56.16 | 64.55 | 66.68 | 54.91 | 60.65 |
| Employee cost | 4.17 | 4.20 | 4.46 | 4.33 | 3.90 | 3.42 | 3.24 |
| EBITDA | (0.29) | 2.57 | 2.40 | 2.34 | 2.41 | 1.73 | (0.70) |
| EBITDA margin | -0.6% | +5.0% | +4.1% | +3.5% | +3.5% | +3.1% | -1.2% |
| Depreciation | 0.89 | 1.26 | 1.29 | 1.25 | 0.89 | 0.71 | 0.29 |
| Interest | 0.81 | 0.93 | 0.83 | 0.53 | 0.37 | 0.29 | 0.23 |
| Profit before tax | (1.81) | 0.43 | 0.58 | 0.69 | 1.24 | 0.85 | (1.17) |
| Tax | 0.12 | 0.16 | 0.16 | 0.18 | 0.44 | 0.09 | (0.43) |
| Net profit | 0.03 | 0.27 | 0.42 | 0.92 | 0.80 | 0.77 | (0.74) |
| Net profit margin | +0.1% | +0.5% | +0.7% | +1.4% | +1.2% | +1.4% | -1.2% |
| EPS (₹) | (2.97) | 0.41 | 0.65 | 0.75 | 1.20 | 1.18 | (1.13) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 |
| Reserves & surplus | 2.00 | 3.92 | 3.61 | 3.19 | 2.82 | 2.05 | 0.90 |
| Shareholders' funds (net worth) | 8.51 | 10.43 | 10.12 | 9.70 | 9.33 | 8.56 | 7.41 |
| Secured loans | 8.78 | 11.23 | 12.34 | 2.67 | 1.36 | 0.38 | 0.32 |
| Unsecured loans | 2.20 | 1.48 | 2.52 | 3.18 | 2.54 | 2.22 | 0.41 |
| Total debt | 10.98 | 12.71 | 14.86 | 5.85 | 3.90 | 2.60 | 0.73 |
| Total liabilities | 20.58 | 24.63 | 26.50 | 16.86 | 14.51 | 11.45 | 8.51 |
| Assets | |||||||
| Gross block | 4.65 | 8.82 | 9.12 | 9.16 | 6.41 | 5.50 | 2.29 |
| Net block | 1.87 | 2.29 | 3.69 | 5.03 | 3.53 | 3.51 | 1.12 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 |
| Inventories | 15.01 | 13.10 | 12.00 | 11.37 | 8.66 | 5.18 | 4.60 |
| Sundry debtors | 15.70 | 19.54 | 20.73 | 21.70 | 20.74 | 18.88 | 22.24 |
| Cash & bank balances | 2.91 | 1.80 | 0.93 | 1.64 | 1.51 | 1.70 | 2.09 |
| Loans & advances | 1.48 | 2.92 | 1.89 | 2.80 | 2.50 | 1.73 | 2.89 |
| Total current assets | 35.10 | 37.36 | 35.55 | 37.51 | 33.41 | 27.49 | 31.82 |
| Total current liabilities | 16.63 | 15.99 | 13.75 | 26.64 | 23.38 | 20.75 | 25.48 |
| Net working capital | 18.47 | 21.37 | 21.80 | 10.87 | 10.03 | 6.74 | 6.34 |
| Total assets | 20.58 | 24.63 | 26.50 | 16.86 | 14.51 | 11.45 | 8.51 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.79 | 0.91 | 1.62 | 1.51 | 1.57 | 10.35 | 1.67 |
| Net cash from operating activities | 4.06 | 3.83 | (9.06) | 1.52 | (0.38) | (8.41) | 0.45 |
| Net cash from investing activities | 0.00 | 0.14 | 0.11 | (1.47) | 0.00 | 0.15 | 0.01 |
| Net cash from financing activities | (2.95) | (3.08) | 8.24 | 0.06 | 0.31 | (0.52) | (0.03) |
| Net change in cash | 1.11 | 0.88 | (0.71) | 0.11 | (0.07) | (8.78) | 0.43 |
| Closing cash | 2.91 | 1.80 | 0.93 | 1.64 | 1.51 | 1.70 | 2.09 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -8.8% | -12.2% | -12.5% | -3.2% | +22.0% | -5.5% | - |
| EBITDA growth | -111.3% | +7.1% | +2.6% | -2.9% | +39.3% | +347.1% | - |
| PBT growth | - | -25.9% | -15.9% | -44.4% | +45.9% | +9998.0% | - |
| Net income growth | -88.9% | -35.7% | -54.4% | +15.0% | +3.9% | +204.1% | - |
| Revenue CAGR (3Y) | -11.2% | -9.4% | +1.1% | +3.7% | +0.9% | -7.6% | -9.6% |
| EBITDA CAGR (3Y) | - | +2.2% | +11.5% | - | +5.9% | -2.2% | - |
| Profitability & leverage | |||||||
| Net income margin | -4.1% | +0.5% | +0.7% | +0.8% | +1.2% | +1.3% | -1.2% |
| Return on capital employed | +4.7% | +5.3% | +6.5% | +11.4% | +12.3% | +11.5% | -10.7% |
| Return on net worth | +0.2% | +2.6% | +4.2% | +9.5% | +8.7% | +9.6% | -9.3% |
| Debt / equity | 1.25 | 1.34 | 1.04 | 0.51 | 0.36 | 0.21 | 0.08 |
| Long-term debt / equity | 0.06 | 0.11 | 0.23 | 0.27 | 0.22 | 0.14 | 0.04 |
| Interest cover | -68.64 | 70.99 | 74.77 | 48.62 | 24.34 | 28.43 | -23.23 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 6.97 | 5.73 | 6.41 | 8.59 | 11.60 | 14.54 | 26.47 |
| Inventory turnover | 3.34 | 4.10 | 5.01 | 6.68 | 9.98 | 11.58 | 13.25 |
| Debtors turnover | 2.66 | 2.55 | 2.76 | 3.15 | 3.49 | 2.75 | 2.54 |
| EPS (₹) | (2.97) | 0.41 | 0.65 | 0.75 | 1.20 | 1.18 | (1.13) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 13.08 | 16.01 | 15.55 | 14.91 | 14.34 | 13.16 | 11.38 |
Web traffic of Zenlabs
The website of Zenlabs (zenlabsethica.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 19.8% vs previous month
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Zenlabs (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 5,180 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.21 B | 25,870 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zenlabs
Complete news archive for Zenlabs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zenlabs
Zenlabs was founded in 2008.
Zenlabs is headquartered in Chandigarh, India.
Sanjeev Kumar is the CEO of Zenlabs, as recorded in our data.
Zenlabs has 16 employees.
The primary company behind Zenlabs, Zenlabs Ethica Limited, reported revenue of ₹47.10 Cr for FY 2026, down 9% year on year.
Zenlabs was established in 2008 in Chandigarh, India, within the pharmaceutical sector. Focus is placed on the production of drugs targeting various therapeutic areas. Operations are conducted from the companys base in India, serving needs in healthcare through manufacturing processes. Leadership is provided by Managing Director and CEO Sanjeev Kumar, with regulatory details including DIN 01154896 and PAN ACSPK6038N noted for compliance. The domain zenlabsethica.com supports online presence.
Zenlabs offers Analgesics and Anti-Inflammatory Drugs and Nutraceuticals.
Yes, Zenlabs is publicly traded on BSE under the ticker symbol ZENLABS.
Zenlabs operates through Zenlabs Ethica Limited.
The legal entities of Zenlabs currently have 6 directors, including Sanjeev Singal, Himjyoti, Anurag Malhotra and others.